ZYMEWORKS INC. Forum: Community User: Karmate1

Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms https://www.businesswire.com/news/home/20210803005452/en/Zymeworks-Announces-Milestone-Payment-as-Janssen-Achieves-First-Patient-Dosed-for-its-Bispecific-Antibody-Utilizing-Zymeworks%E2%80%99-Azymetric%E2%84%A2-and-EFECT%E2%84%A2-Therapeutic-Platforms

Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy https://www.businesswire.com/news/home/20210728005348/en/Zymeworks-Announces-First-Patient-with-Advanced-HER2-Positive-Breast-Cancer-Dosed-with-Zanidatamab-in-Combination-with-Tukysa%C2%AE-Tucatinib-and-Chemotherapy

Zymeworks: Drop Due To Low Differentiation Against Competition https://seekingalpha.com/article/4437851-zymeworks-drop-due-to-low-differentiation-against-competition Summary • Zymeworks dropped a lot despite positive data. • The data was unable to differentiate ZW49 from rivals. • The company needs to do more to prove its unique selling point. ...

Zymeworks nears session highs on takeover speculation https://seekingalpha.com/news/3711962-zymeworks-nears-session-highs-on-takeover-speculation Zymeworks (NYSE:ZYME) jumped 9.3% on a report that the company has received a takeover approach and is working with a bank to consider other interest. The unidentified party is said to have bid around $50/share, according to a StreetInsider report, which cited an unidentified source. Zymeworks didn't respond to StreetInsider request for comment. Zymeworks shares plunged in late January after posting some results from ZW49 study. Citi also downgraded the shares to neutral in late January before the study results were released. The shares had traded near $57 in early January before the study results were published. Zymeworks short interest 3.7% of float.

🧐🧐🧐

Zymeworks Reports 2021 First Quarter Financial Results https://www.businesswire.com/news/home/20210505006039/en/Zymeworks-Reports-2021-First-Quarter-Financial-Results

https://marketwirenews.com/news-releases/zymeworks-showcases-preclinical-assets-including-new-7254209322201100.html

Zymeworks Q4 EPS $(0.74) Up From $(1.06) YoY, Sales $15.68M Up From $1.88M YoY https://pub.webull.com/us/news-html/82fb744f222d40ae8c80341ca1665e90.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en Zymeworks (NYSE:ZYME) reported quarterly losses of $(0.74) per share. This is a 30.19 percent increase over losses of $(1.06) per share from the same period last year. The company reported $15.68 million in sales this quarter. This is a 735.38 percent increase over sales of $1.88 million the same period last year.

https://www.businesswire.com/news/home/20210209006171/en/Zymeworks-Expands-Commercial-Team-and-Creates-New-RD-Role

Zymeworks Moves Antibody-Drug Conjugate to Expansion Cohort Stage in Ongoing Phase 1 Trial -- Shares Drop 26% in Late Trading https://pub.webull.com/us/news-html/4f7b2785ef7a45b2aa3dda7cdbcc86b2.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en&theme=1

Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development https://finance.yahoo.com/news/zymeworks-advances-her2-bispecific-antibody-221500187.html • Active drug with multiple confirmed responses and stable disease observed in several tumor types • Differentiated safety profile with the majority of adverse events being grade 1 or 2 • Expansion cohorts open and enrolling patients at 2.5 mg/kg once every three weeks • Maximum tolerated dose not established, dose escalation continues in parallel ...

Zymeworks (ZYME) PT Raised to $74 at Raymond James https://www.streetinsider.com/dr/news.php?id=17833681&gfv=1

Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium https://www.businesswire.com/news/home/20210115005163/en/Zanidatamab-Data-Highlight-Durable-Antitumor-Activity-in-HER2%E2%80%91Expressing-Biliary-Tract-and-Gastroesophageal-Cancers-at-ASCO-Gastrointestinal-Cancers-Symposium • Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers • Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021 ...

Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities https://www.businesswire.com/news/home/20210111005427/en/Zymeworks-Highlights-2020-Achievements-and-Announces-Corporate-Priorities

ImmunoPrecise partners with Canada’s NRC to develop SARS-CoV-2 therapeutics https://seekingalpha.com/news/3643678-immunoprecise-partners-canada-s-nrc-to-develop-sars-covminus-2-therapeutics ... The project is also in partnership with Zymeworks Inc. (ZYME) for the design and development of IPA's lead antibody candidates.  ...

Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals https://seekingalpha.com/article/4394251-zymeworks-oncology-drug-discovery-company-major-big-pharma-deals Summary ZYME has a set of 3 drug discovery/development platforms which have generated major deals from big pharma. Its self-owned asset ZW25 is inching closer towards registrational stage. The company is also solid on cash and looks like a future winner. ...